Eli Lilly & Co. (LLY) Tops Q2 EPS by $1.17, Beats on Revenue; Offers Upbeat FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eli Lilly (LLY) PT Raised to $1,150 at BofA Securities
August 9, 2024 5:56 AM EDTBofA Securities analyst Geoff Meacham raised the price target on Eli Lilly (NYSE: LLY) to $1,150.00 (from $1,000.00) while maintaining a Buy rating.
The analyst comments "LLY shares traded with strength today (+9.5%; DRG index: +4%) following the continued outperformance from Lillys incretin portfolio, including Mounjaro (Type 2 diabetes) and Zepbound (obesity). Importantly, given managements... More
Eli Lilly stock jumps 10% on annual guidance hike, strong Q2 top and bottom line
August 8, 2024 6:58 AM EDT(Updated - August 8, 2024 9:34 AM EDT)
Eli Lilly & Co. (NYSE: LLY) reported much stronger-than-expected earnings for the fiscal Q2 2024 and raised its guidance for the full year.
The drugmakers shares surged more than 10% at the Thursday market open.
For the second quarter, Lilly posted earnings per share (EPS) of $3.92, significantly above the consensus estimate of $2.75. Revenue rose to $11.3 billion, also exceeding analyst estimates.
Revenue for its Trulicity... More
